EpiCor

Indication: Allergy symptoms

Source: Advances in Therapy 2009;26(8):795-804.

Research: For this randomized, double-blind, placebo-controlled study, 96 healthy test subjects with recent history of seasonal allergies and allergic rhinitis (AR) were given either a once-daily 500 mg dose of EpiCor or placebo over a 12-week period of the highest recorded concentrations of total pollen counts for the Midwest geographic area.

Results: Researchers found the immune-balancing supplement EpiCor significantly reduced the severity of allergy symptoms. Results were measured with in-clinic examinations, validated questionnaires and diaries and serologic analysis at baseline, 6 and 12 weeks. The study found that EpiCor significantly reduced the severity of specific AR symptoms, including nasal congestion and rhinorrhea (runny nose).